167 related articles for article (PubMed ID: 37440307)
1. Creating an Innovative Artificial Intelligence-Based Technology (TCRact) for Designing and Optimizing T Cell Receptors for Use in Cancer Immunotherapies: Protocol for an Observational Trial.
Bujak J; Kłęk S; Balawejder M; Kociniak A; Wilkus K; Szatanek R; Orzeszko Z; Welanyk J; Torbicz G; Jęckowski M; Kucharczyk T; Wohadlo Ł; Borys M; Stadnik H; Wysocki M; Kayser M; Słomka ME; Kosmowska A; Horbacka K; Gach T; Markowska B; Kowalczyk T; Karoń J; Karczewski M; Szura M; Sanecka-Duin A; Blum A
JMIR Res Protoc; 2023 Jul; 12():e45872. PubMed ID: 37440307
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
Simister PC; Border EC; Vieira JF; Pumphrey NJ
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851311
[TBL] [Abstract][Full Text] [Related]
3. Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.
Wei T; Leisegang M; Xia M; Kiyotani K; Li N; Zeng C; Deng C; Jiang J; Harada M; Agrawal N; Li L; Qi H; Nakamura Y; Ren L
Oncoimmunology; 2021 May; 10(1):1929726. PubMed ID: 34104546
[TBL] [Abstract][Full Text] [Related]
4. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
[No Abstract] [Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges.
Pang Z; Lu MM; Zhang Y; Gao Y; Bai JJ; Gu JY; Xie L; Wu WZ
Biomark Res; 2023 Dec; 11(1):104. PubMed ID: 38037114
[TBL] [Abstract][Full Text] [Related]
7. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
8. An Artificial Intelligence-Driven Digital Health Solution to Support Clinical Management of Patients With Long COVID-19: Protocol for a Prospective Multicenter Observational Study.
Fuster-Casanovas A; Fernandez-Luque L; Nuñez-Benjumea FJ; Moreno Conde A; Luque-Romero LG; Bilionis I; Rubio Escudero C; Chicchi Giglioli IA; Vidal-Alaball J
JMIR Res Protoc; 2022 Oct; 11(10):e37704. PubMed ID: 36166648
[TBL] [Abstract][Full Text] [Related]
9. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
10. Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing.
Lu YC; Zheng Z; Lowery FJ; Gartner JJ; Prickett TD; Robbins PF; Rosenberg SA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321276
[TBL] [Abstract][Full Text] [Related]
11. Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.
Tate T; Matsumoto S; Nemoto K; Leisegang M; Nagayama S; Obama K; Nakamura Y; Kiyotani K
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831375
[TBL] [Abstract][Full Text] [Related]
12. CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.
Baumgaertner P; Schmidt J; Costa-Nunes CM; Bordry N; Guillaume P; Luescher I; Speiser DE; Rufer N; Hebeisen M
Front Immunol; 2022; 13():973986. PubMed ID: 36032094
[TBL] [Abstract][Full Text] [Related]
13. Molecular Rules Underpinning Enhanced Affinity Binding of Human T Cell Receptors Engineered for Immunotherapy.
Crean RM; MacLachlan BJ; Madura F; Whalley T; Rizkallah PJ; Holland CJ; McMurran C; Harper S; Godkin A; Sewell AK; Pudney CR; van der Kamp MW; Cole DK
Mol Ther Oncolytics; 2020 Sep; 18():443-456. PubMed ID: 32913893
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
[TBL] [Abstract][Full Text] [Related]
15. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
16. Detection of mutant antigen-specific T cell receptors against multiple myeloma for T cell engineering.
Okada M; Shimizu K; Nakazato H; Yamasaki S; Fujii SI
Mol Ther Methods Clin Dev; 2023 Jun; 29():541-555. PubMed ID: 37359417
[TBL] [Abstract][Full Text] [Related]
17. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
[TBL] [Abstract][Full Text] [Related]
18. Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers.
Zhang H; Liu L; Zhang J; Chen J; Ye J; Shukla S; Qiao J; Zhan X; Chen H; Wu CJ; Fu YX; Li B
Clin Cancer Res; 2020 Mar; 26(6):1359-1371. PubMed ID: 31831563
[TBL] [Abstract][Full Text] [Related]
19. Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia.
Zhou W; Yu J; Li Y; Wang K
Exp Hematol Oncol; 2022 Nov; 11(1):100. PubMed ID: 36384590
[TBL] [Abstract][Full Text] [Related]
20. Predictive Monitoring-Impact in Acute Care Cardiology Trial (PM-IMPACCT): Protocol for a Randomized Controlled Trial.
Keim-Malpass J; Ratcliffe SJ; Moorman LP; Clark MT; Krahn KN; Monfredi OJ; Hamil S; Yousefvand G; Moorman JR; Bourque JM
JMIR Res Protoc; 2021 Jul; 10(7):e29631. PubMed ID: 34043525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]